Orchard Therapeutics PLC (ORTX) Gets a Buy Rating from Cowen & Co.

By Carrie Williams

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Orchard Therapeutics PLC (ORTXResearch Report), with a price target of $27. The company’s shares closed last Monday at $14.70.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 20.2% and a 44.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Orchard Therapeutics PLC with a $26.50 average price target, which is a 76.7% upside from current levels. In a report issued on August 29, Oppenheimer also initiated coverage with a Buy rating on the stock with a $26 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.64 and a one-year low of $8.65. Currently, Orchard Therapeutics PLC has an average volume of 223.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.